Tag Archives: PulseSight Therapeutics

BIOTECH

EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder

US$13.75M financing completed to accelerate clinical pathway and global commercialisation Establishment of NinaMED Pty Ltd,...

Read more

BIOTECH

Hope for Dry AMD: Novel Gene Therapy Completes First Human Safety Trial

Paris, France – April 23, 2026 – In a significant development for the millions suffering...

Read more

BIOTECH

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

Paris, France, January 22, 2026 – PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing...

Read more

BIOTECH

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing...

Read more

BIOTECH

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing...

Read more